Dani P. Bolognesi, PhD., Director. Dr. Bolognesi is Professor Emeritus at Duke University, is Founder, CEO and CSO at Trimeris, Inc., a public company that developed Fuzeon®, a first-in-class HIV fusion inhibitor, in collaboration with Hoffmann-La Roche. He is also CEO and Chairman of b3Bio, Inc; CEO, Enci Therapeutics, Inc., CEO at C2 Regenerate, Inc and CSO of Istari Oncology, Inc.